Download - “Sequencing cancer genomes” - Illumina
![Page 1: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/1.jpg)
“Sequencing cancer genomes”
Phil Stephens
Wellcome Trust Sanger Institute
![Page 2: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/2.jpg)
in situ cancer
Invasive cancer
Metastatic cancer
Pre-cancerous
lesion
Genomic instability
Genetic Instability
~10 ‘Driver mutations’
1000s ‘Passenger Mutations’
ExposureUV light
Tobacco smoke
Breast, Lung, Colorectal cancers etc.....
![Page 3: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/3.jpg)
Base Substitutions Insertions deletions
Copy number changes Rearrangements
Cancer genome harbour multiple classes of mutation
![Page 4: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/4.jpg)
Five years of data per day vs capillary sequencing
Detect all classes of mutation in a single experiment
Screen the entire genome for mutations
Screen targeted regions: Coding exons
Illumina Genome Analyser
Sequencing by synthesis
![Page 5: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/5.jpg)
• 33,345 somatic substitutions
• 88% sensitivity
• 97% specificity
• 31 Somatic rearrangements
• 41 Copy number changes
• 36 Small insertions & deletions
Comprehensive catalogue of somatic mutations
from a malignant melanoma genome
![Page 6: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/6.jpg)
Substitution mutation spectrum
Total
Mutations
Early
Mutations
Late
Mutations
C>T common due to UV light exposure
C>T 82%
C>T 53%
P <0.0001C>A 2%
C>A 19%
![Page 7: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/7.jpg)
Somatic mutations in genic footprints
Expected = 40%
Observed = 29%
Distribution of somatic substitutions
![Page 8: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/8.jpg)
Stalled RNA
polymerase
Bulky adduct on
transcribed strand
mRNA
Transcription-coupled repair
![Page 9: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/9.jpg)
Strand bias:- Somatic C>T substitutions
T
U4000
3000
2000
1000
0
Num
ber
of
muta
tion
s
P <0.0001
![Page 10: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/10.jpg)
Strand bias:- ALL somatic substitutions
T
U4000
3000
2000
1000
0
Num
ber
of
muta
tion
s
P <0.0001
![Page 11: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/11.jpg)
Transcription coupled repair only accounts
for only a third of the deficit of mutations
over protein coding gene footprints
![Page 12: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/12.jpg)
Novel „expression linked‟ repair mechanismM
uta
tion p
revale
nce (
per
Mb)
30
20
10
0
Expression levels (log2)
Effect of strand of mutation: p<0.0001
Effect of expression level: p<0.0001
C>T non-transcribed
strandC>T transcribed
strand
4 5 6 7 8 9
![Page 13: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/13.jpg)
Novel „expression linked‟ repair mechanismM
uta
tion p
revale
nce (
per
Mb)
30
20
10
0
Expression levels (log2)
Effect of strand of mutation: p<0.0001
Effect of expression level: p<0.0001
C>T non-transcribed
strandC>T transcribed
strand
4 5 6 7 8 9
![Page 14: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/14.jpg)
Feedback for our first cancer genome
![Page 15: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/15.jpg)
Objections to sequencing cancer genomes:
1) “Cancer is too heterogeneous for sequencing to uncover
therapeutically relevant mutations”.
2) “All of the major cancer genes/pathways have already
been discovered”
3) “Sequencing large numbers of cancer genomes is not the
best use of the technology, and will have very limited
clinical use”
4) “Sequencing is unlikely to provide insights into
metastasis, the dominant cause of mortality in cancer”
![Page 16: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/16.jpg)
Objections to sequencing cancer genomes:
1) “Cancer is too heterogeneous for sequencing to uncover
therapeutically relevant mutations”.
2) “All of the major cancer genes/pathways have already
been discovered”
3) “Sequencing large numbers of cancer genomes is not the
best use of the technology, and will have very limited
clinical use”
4) “Sequencing is unlikely to provide insights into
metastasis, the dominant cause of mortality in cancer”
![Page 17: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/17.jpg)
BRAF is an oncogene 50% of Melanoma
T1799A V600E
BRAF is not important Melanoma
BRAF is not a good drug target
Melanoma is too complex to treat effectively
![Page 18: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/18.jpg)
Selective inhibitor of BRAF
(Plexxicon 4032)
Before 15 days after
Courtesy of Dr Grant McArthur
![Page 19: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/19.jpg)
Similar results are being seen with:
PARP inhibitors BRCA1/BRCA2 null breast cancer
EGFR inhibitors EGFR mutated lung cancer
ABL inhibitors BCR/ABL positive CML
![Page 20: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/20.jpg)
Objections to sequencing cancer genomes:
1) “Cancer is too heterogeneous for sequencing to uncover
therapeutically relevant mutations”.
2) “All of the major cancer genes/pathways have already
been discovered”
3) “Sequencing large numbers of cancer genomes is not the
best use of the technology, and will have very limited
clinical use”
4) “Sequencing is unlikely to provide insights into
metastasis, the dominant cause of mortality in cancer”
![Page 21: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/21.jpg)
Investigate all protein coding exons/miRNA’s simultaneously
● Protein coding genes 21,416
● Micro RNAs 1664
Can process large numbers of samples
High sensitivity in primary tumours (normal contamination)
Cancer Exome Sequencing
Human exome
![Page 22: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/22.jpg)
18 samples from a common epithelial tumour
9/18 had a truncating mutation in a novel TSG
136/388 follow up tumours had truncating mutations
in same gene
Potentially „druggable‟ using a cheap, approved,
existing cancer drug
Cancer Exome Sequencing
![Page 23: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/23.jpg)
3 x ER Negative Breast cancers
25 x ERPositive Breast cancers
Cancer Exome Sequencing
![Page 24: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/24.jpg)
Numbers of somatic substitutions per sample
ER negative
Mean 75, (range 29-100)
![Page 25: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/25.jpg)
Numbers of somatic substitutions per sample
ER positive
Mean 19.7, (range 1-45)
![Page 26: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/26.jpg)
Somatic subs in known breast cancer genes
PD3995a AKT1 E17K
PD3995a NF1 G-1T
PD3994a PIK3CA N345K
PD3989a PIK3CA E545K
PD3856a PIK3CA H1047R
PD3857a PIK3CA H1047R
PD3888a PIK3CA H1047R
PD3983a PIK3CA H1047R
PD3985a PIK3CA H1047R
PD3992a PIK3CA H1047R
PD3996a PTEN Y27D
PD3991a TP53 G245S
PD4002a TP53 H179Y
PD3987a TP53 Y220C
PD3986a TP53 G+1A
PD3985a TP53 R306X
![Page 27: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/27.jpg)
PD3849a CDH1 V193X
PD3984a MAP2K4 V151X
PD3992a MAP2K4 I81X
PD3989a PTEN L370X
PD3995a GATA3 N352X
PD3988a GATA3 N352X
PD4004a GATA3 Read through
Somatic indels in known breast cancer genes
![Page 28: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/28.jpg)
638 somatic substitutions
38 small INDELS
![Page 29: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/29.jpg)
Mutations in a „novel pathway‟
in >60% of ER+ breast cancer
![Page 30: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/30.jpg)
Several potential new susceptibility alleles are
being further evaluated
CHEK2 BRCA1
W411X 4 bp deletion
Exome sequencing & susceptibility alleles
![Page 31: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/31.jpg)
Objections to sequencing cancer genomes:
1) “Cancer is too heterogeneous for sequencing to uncover
therapeutically relevant mutations”.
2) “All of the major cancer genes/pathways have already
been discovered”
3) “Sequencing large numbers of cancer genomes is not the
best use of the technology, and will have very limited
clinical use”
4) “Sequencing is unlikely to provide insights into
metastasis, the dominant cause of mortality in cancer”
![Page 32: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/32.jpg)
Rearrangement characterisation
![Page 33: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/33.jpg)
73 Chromosomes, 37 structural abnormalities
Breast cancer karyotype
![Page 34: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/34.jpg)
238 somatic structural variants Patterns of variation
Breast cancer HCC38 (Triple neg)
150
100
50
0
![Page 35: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/35.jpg)
What are these structural variants doing?
![Page 36: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/36.jpg)
T N
Chromosome 3 position (Mb)
48 48.2 48.4 48.6 48.8 49 49.2 49.4
Co
py n
um
be
r
6
5
4
3
2
1
0
T N
FISH confirmation of
tandem duplicationSLC26A6/PRKAR2A in frame fusion gene
5’ UTR 3’ UTR
SLC26A6 PRKAR2A
(Exons 1-17) (Exons 4-11)
600
200
400
bps
164 kb tandem duplication Genomic PCR
![Page 37: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/37.jpg)
RT-PCR
MGLADASGPRDTQALLSATQAMDLRRRDYHMERPLLNQEHLEELGRWGSAPRTHQWRTWLQCSRARAYALLLQHLPVLVWLPRYPVRDWLLGDLLSGLSVAIMQLPQGLAYALLAGLPPVFGLYSSFYPVFIYFLFGTSRHISVGTFAVMSVMVGSVTESLAPQALNDSMINETARDAARVQVASTLSVLVGLFQVGLGLIHFGFVVTYLSEPLVRGYTTAAAVQVFVSQLKYVFGLHLSSHSGPLSLIYTVLEVCWKLPQSKVGTVVTAAVAGVVLVVVKLLNDKLQQQLPMPIPGELLTLIGATGISYGMGLKHRFEVDVVGNIPAGLVPPVAPNTQLFSKLVGSAFTIAVVGFAIAISLGKIFALRHGYRVDSNQELVALGLSNLIGGIFQCFPVSCSMSRSLVQESTGGNSQVAGAISSLFILLIIVKLGELFHDLPKAVLAAIIIVNLKGMLRQLSDMRSLWKANRADLLIWLVTFTATILLNLDLGLVVAVIFSLLLVVVRTQMPHYSVLGQVPDTDIYRDVAEYSEAKEVRGVKVFRSSATVYFANAEFYSDALKQRCGVDVDFLISQKKKLLKKQEQLKLKQLQKEEKLRKQAASPKGASVSINVNTSLEDMRSNNVEDCKMVIHPKTDEQRCRLQEACKDILLFKNLDQEQLSQVLDAMFERIVKADEHVIDQGDDGDNFYVIERGTYDILVTKDNQTRSVGQYDNRGSFGELALMYNTPRAATIVATSEGSLWGLDRVTFRRIIVKNNAKKRKMFESFIESVPLLKSLEVSERMKIVDVIGEKIYKDGERIITQGEKADSFYIIESGEVSILIRSRTKSNKDGGNQEVEIARCHKGQYFGELALVTNKPRAASAYAVGDVKCLVMDVQAFERLLGPCMDIMKRNISHYEEQLVKMFGSSVDLGNLGQStop
Predicted 914 amino acid fusion protein
T N
600
200
400
bps
![Page 38: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/38.jpg)
Five expressed in frame fusion genes
2 generated by tandem duplications
3 generated by large inversions
![Page 39: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/39.jpg)
![Page 40: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/40.jpg)
Potential applications in healthcare
![Page 41: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/41.jpg)
Selective inhibitor of BRAF V600E
(Plexxicon 4032)
Before 15 days after
Courtesy of Dr Grant McArthur
![Page 42: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/42.jpg)
Personalised Haematology
Time (months)
Risk stratification
Therapy durationPrediction of
relapse
Tu
mo
ur
ce
lls
Accurate ascertainment of tumour burden in
response to chemotherapy
![Page 43: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/43.jpg)
~two hundred tumours and identified at least
one somatically acquired rearrangement in
sample (range 1-245)
Solid tumour rearrangement screens
![Page 44: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/44.jpg)
Identify tumour-specific rearrangements
from cancer DNA
Design & test quantitative assay for
rearrangements
Extract DNA from plasma
(10-20mL blood sample)
Quantify tumour DNA
2 weeks
~£2,500
1 week
£250
½ day
£50
½ day
£50
Work flow
![Page 45: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/45.jpg)
Detecting 1 copy of tumour genome
![Page 46: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/46.jpg)
Serial measurements
![Page 47: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/47.jpg)
Potential healthcare applications
• Monitoring tumour response to therapy in real-time
– Reduce toxicity, prevent drug wastage
• Identifying disease relapse before clinically evident
– Pre-emptive therapy
• Choosing intensity of adjuvant therapy based on risk
stratification
• Surrogate marker of cell kill in early phase clinical trials
![Page 48: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/48.jpg)
Objections to sequencing cancer genomes:
1) “Cancer is too heterogeneous for sequencing to uncover
therapeutically relevant mutations”.
2) “All of the major cancer genes/pathways have already
been discovered”
3) “Sequencing large numbers of cancer genomes is not the
best use of the technology, and will have very limited
clinical use”
4) “Sequencing is unlikely to provide insights into
metastasis, the dominant cause of mortality in cancer”
![Page 49: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/49.jpg)
Dynamics of metastasis in pancreatic cancer
Patient Patient Patient
1 5 9
PCR genotype multiple
metastases
PCR genotype multiple
metastases
PCR genotype multiple
metastases
![Page 50: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/50.jpg)
Ind
ex
No
rmal
1 2 3 4 5 Wate
r
Shared in all metastases
Partially shared
Unique to index metastasis
Dynamics of metastasis in pancreatic cancer
![Page 51: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/51.jpg)
Inter-individual differences
0
5
10
15
20
25
30
35
40
45
50
Private
Partially shared
Omnipresent
![Page 52: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/52.jpg)
Phylogenetic relationships between
metastases within same patient
Rearrangements 1-56
Index
4
5
1
2
3
Primary
Germline
![Page 53: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/53.jpg)
Phylogenetic tree
![Page 54: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/54.jpg)
Evidence for convergent evolution
![Page 55: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/55.jpg)
Organ-specific signature
![Page 56: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/56.jpg)
Dynamics of genomic instability and metastasis
Primary tumour
Capacity to initiate
metastasis
Secondary metastasis
Tertiary metastasis
Molecular time
![Page 57: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/57.jpg)
Conclusions
1) “Although cancer is heterogeneous, sequencing is an
effective tool to uncover therapeutically relevant
mutations”.
2) “There are major cancer genes and pathways yet to be
discovered”
3) “Sequencing large numbers of cancer genomes has
massive clinical utility and will transform the way that
cancer is treated and patients are managed”
4) Sequencing can generate ‘dramatic insights’ into
modes and mechanisms of metastasis
![Page 58: “Sequencing cancer genomes” - Illumina](https://reader033.vdocument.in/reader033/viewer/2022051801/62815a3d7f6cf003cd6b43fe/html5/thumbnails/58.jpg)
Dave McBride Mike Quail
Meng-lay lin Dan Turner
Patrick Tarpey Harold Swerdlow
Stuart Mclaren
Keiran Raine David Bentley
Dave Jones Keira Cheetham
Ignacio Varela Mark Ross
Laura Mudie
Lucy Stebbings
Catherine Leroy
Jon Teague